Given that inflammatory hepatocellular adenoma is characterized by the activation of the IL-6/JAK/STAT pathway, we suspect that this efficacy may be associated with the suppression of IL-6 [92]. This evidence concerns the gene IL6 and hepatocellular adenoma.